CA-XSOLLA
3.5.2021 16:14:09 CEST | Business Wire | Press release
Xsolla, the video game commerce company powered by its Transaction Engine and Business Engine to help developers and publishers market, sell, connect and optimize their games globally, is hosting a reimagined Game Carnival on May 11-12, 2021. The innovative virtual game industry event that hosted thousands of attendees, 220+ exhibitors, and 5000+ meetings in 2020 will have a new immersive experience, updated networking features, two speaking stages with dozens of industry experts, and 1-on-1 private meeting spaces. Razer, Sega, and many more will be providing giveaways that a few lucky registrants and attendees can win leading up to and during the event (https://gamecarnivalevent.com/ ).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210503005347/en/
“Xsolla supports digital events, such as Game Carnival, as part of our ongoing commitment to help game developers connect, learn and share with fellow industry professionals,” said Chris Hewish, President of Xsolla. “Inspired by the success and learnings from last year’s events, we are bringing Game Carnival back as a wholly reimagined experience that delivers even more value to indie game developers, publishers, and all industry attendees.”
Game Carnival 2021’s virtual world is built on GenXP’s rich platform environment. The immersive experience offers a range of features to facilitate education and industry networking, including:
- Drop in and out of private meeting spaces either scheduled or on-demand. Engage with your clients or friends in a secure, private setting
- Dynamic speaking and presentation environments, hosting industry luminaries on a range of topics
- Customize your look and experience with interactive avatars
- Share and collect contact information, right to your inbox with the click of a button
- Cross-platform support for easy event access with only a web browser required
- Livestream from social platforms
"Xsolla has been steadfast in their mission to innovate and provide new ways to drive video game commerce forward," said Vince McMullin, CEO of GenXP. "They have been a tremendous partner to work with as we use the GenXP platform to level-up Game Carnival 2021 and propel virtual event technologies to new heights of performance, accessibility and inclusivity."
For additional information on Game Carnival and a full list of exhibitors, visit https://gamecarnivalevent.social/press .
About Xsolla:
Xsolla is the video game commerce company, powered by its Transaction Engine and Business Engine, that helps developers and publishers market, sell, connect and optimize their games globally. Serving only the video game industry, the Xsolla Transaction Engine powers the full suite of cloud-based tools to promote and monetize projects, while Xsolla Business Engine provides clients with the roadmap to maximize those tools, and connect them with industry partnerships to expand their business. The two work seamlessly together -- for businesses of all sizes, from indie to enterprise -- to solve the complexities of distribution, marketing and monetization so they can increase their audience, sales and revenue. Headquartered in Los Angeles, with offices worldwide, Xsolla operates as a merchant and seller of record for major gaming entities like Valve, Twitch, Roblox, Ubisoft, Epic Games and KRAFTON. For more information, please visit www.xsolla.com .
About GenXP:
GenXP is a subsidiary of TurboPlay Corporation, a pioneer in scalable, digital marketplace technologies. Based out of New Brunswick, Canada, GenXP leverages these technologies to generate custom virtual experiences for the new [not] normal, and beyond. With hard work and innovation, we push the boundaries of technological possibilities to shape new realities, creating engaging, social, experiential memories. Our virtual event platform and services empower our clients to engage their audiences, fans, colleagues, and customers in virtually limitless ways. Say hello@genxp.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210503005347/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom